Modi Rajeev A. has filed 45 Form 4 transactions, all in Elanco Animal Health (ELAN), with a clear accumulation bias: roughly $195,924 in open-market purchases and zero open-market sales. The two most recent purchases occurred on May 15, 2026, at $99,939, and December 11, 2025, at $95,985, both coded "P" for open-market buys—the only transaction type that reflects discretionary conviction. These purchases stand out against a backdrop of recurring "A" grants, which are compensation awards, not voluntary acquisitions, and "F" withholdings that automatically cover tax obligations.
The pattern reveals a steady, modest stream of equity grants—typically $1,414 to $1,477 every two weeks—interspersed with larger, deliberate cash purchases. The December 2025 and May 2026 buys, totaling nearly $196,000, represent the only discretionary capital deployed, while no "S" (open-market sale) or "D" (sale back to issuer) transactions appear in the filing history. A notable March 1, 2026, cluster includes multiple zero-value "A" grants and a $511,500 "F" tax withholding, suggesting a significant vesting event rather than a trading decision.
Overall, Modi’s activity signals a consistent holder who adds shares opportunistically but never reduces his position. The absence of any sell-side activity, combined with the two substantial purchases spaced six months apart, points to a long-term accumulation strategy in ELAN. The recurring small grants and automatic tax withholdings are routine compensation mechanics, while the two "P" transactions—$95,985 and $99,939—are the only filings that reflect a clear, voluntary bullish stance on the company’s stock.
AI-assisted summary